会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Attribute presenter of object attributes and method for presenting object attributes using the attribute presenter
    • 使用属性呈现器呈现对象属性的对象属性的属性呈现器和方法
    • US08140501B2
    • 2012-03-20
    • US11946547
    • 2007-11-28
    • Song WuPeter Andrew Nicholls
    • Song WuPeter Andrew Nicholls
    • G06F17/30
    • G06F17/30991G06F17/30607Y10S707/956
    • An attribute presenter of object attributes from at least one object includes an attribute controller for determining which attributes to select; an attribute collector for collecting and normalizing the determined attributes from the at least one object; an attribute organizer for organizing the collected and normalized attributes for display; and an attribute viewer for displaying the organized object attributes. A method for presenting object attributes using an attribute presenter includes the steps of determining which object attributes to select using an attribute controller; collecting and normalizing the determined object attributes from at least one object using an attribute collector; organizing the collected and normalized object attributes for display by an attribute organizer; and displaying the organized object attributes by an attribute viewer.
    • 来自至少一个对象的对象属性的属性呈现器包括用于确定要选择的属性的属性控制器; 属性收集器,用于从所述至少一个对象收集和归一化所确定的属性; 用于组织收集和归一化的属性进行显示的属性组织器; 以及用于显示有组织的对象属性的属性查看器。 使用属性呈现器呈现对象属性的方法包括以下步骤:使用属性控制器确定要选择的对象属性; 使用属性收集器从至少一个对象收集和归一化所确定的对象属性; 组织收集和归一化的对象属性以供属性组织者显示; 并通过属性查看器显示有组织的对象属性。
    • 2. 发明申请
    • ATTRIBUTE PRESENTER OF OBJECT ATTRIBUTES AND METHOD FOR PRESENTING OBJECT ATTRIBUTES USING THE ATTRIBUTE PRESENTER
    • 对象属性的属性主体和使用属性提供者呈现对象属性的方法
    • US20090138499A1
    • 2009-05-28
    • US11946547
    • 2007-11-28
    • Peter Andrew NichollsSong Wu
    • Peter Andrew NichollsSong Wu
    • G06F17/30
    • G06F17/30991G06F17/30607Y10S707/956
    • An attribute presenter of object attributes from at least one object includes an attribute controller for determining which attributes to select; an attribute collector for collecting and normalizing the determined attributes from the at least one object; an attribute organizer for organizing the collected and normalized attributes for display; and an attribute viewer for displaying the organized object attributes. A method for presenting object attributes using an attribute presenter includes the steps of determining which object attributes to select using an attribute controller; collecting and normalizing the determined object attributes from at least one object using an attribute collector; organizing the collected and normalized object attributes for display by an attribute organizer; and displaying the organized object attributes by an attribute viewer.
    • 来自至少一个对象的对象属性的属性呈现器包括用于确定要选择的属性的属性控制器; 属性收集器,用于从所述至少一个对象收集和归一化所确定的属性; 用于组织收集和归一化的属性进行显示的属性组织器; 以及用于显示有组织的对象属性的属性查看器。 使用属性呈现器呈现对象属性的方法包括以下步骤:使用属性控制器确定要选择的对象属性; 使用属性收集器从至少一个对象收集和归一化所确定的对象属性; 组织收集和归一化的对象属性以供属性组织者显示; 并通过属性查看器显示有组织的对象属性。
    • 3. 发明授权
    • Method and device for power control in HSDPA
    • HSDPA功率控制方法及装置
    • US08570882B2
    • 2013-10-29
    • US12374823
    • 2007-07-10
    • Song Wu
    • Song Wu
    • H04L1/00H04L12/28
    • H04W52/286H04W52/143H04W52/221H04W52/241H04W52/26H04W52/281H04W52/34H04W52/48
    • The method for power control in HSDPA includes Step A, the UE with the highest priority and having data to be transmitted is selected according to the algorithm, the channel resource is distributed to the UE, and the original power level is set. Step B, the transmission power is deduced when the channel quality meets the condition; Otherwise the CQI is checked, if the value of CQI is under the highest rate level, or the data is the re-transmitting data, the transmission power is increased, or the power is kept the same level. Step C, channel resource and the UE with the highest priority are checked, if there exist, then go to step B, otherwise the method is ended. So the redundant power can be used when several UEs are controlled at the same time, the efficiency and the throughput performance are improved, and the interface is reduced. The device for power controlling is given at the same time.
    • HSDPA中的功率控制方法包括步骤A,根据该算法选择具有最高优先级并具有待传输数据的UE,将信道资源分配给UE,并设置原始功率级别。 步骤B,当信道质量满足条件时,推导出发射功率; 否则,检查CQI,如果CQI的值处于最高速率级别,或者数据是重发数据,则发送功率增加或者功率保持相同的级别。 步骤C,信道资源和优先级最高的UE进行检查,如果存在,则转到步骤B,否则方法结束。 因此,当同时控制多个UE时可以使用冗余功率,提高效率和吞吐量性能,并减少接口。 同时给出功率控制装置。
    • 5. 发明申请
    • TRIACETYL-3-HYDROXYPHENYLADENOSINE AND ITS USE FOR REGULATING BLOOD FAT
    • 三硝基-3-羟基苯基腺苷及其用于调节血液脂肪
    • US20120053143A1
    • 2012-03-01
    • US13255153
    • 2009-03-10
    • Haibo ZhuSong WuLinghua HaoKai QuPing ZhuXing WangWei Li
    • Haibo ZhuSong WuLinghua HaoKai QuPing ZhuXing WangWei Li
    • A61K31/7076C07H1/00A61P3/06C07H19/167
    • A61K31/7076C07H19/167
    • The invention discloses triacetyl-3-hydroxyphenyladenosine represented by formula (I), the preparation, the pharmaceutical composition and the use thereof. Specially, the invention discloses a new compound of 2′,3′,5′-tri-O-acetyl-N6-(3-hydroxyphenyl)adenosine. Using hypoxanthine nucleoside as starting material, the compound is prepared by acetylating with acetic anhydride, chlorinating with thionyl chloride, and being substituted with 3-hydroxy aniline. The invention also discloses the pharmaceutical composition comprising triacetyl-3-hydroxyphenyladenosine. The dosage forms of the said pharmaceutical composition include tablet, capsule, pill, injection, sustained release preparation, controlled release preparation or particulate delivery system. The medicament for treatment or precaution of hyperlipemia prepared by the compound of the invention has the advantages of significant hypolipidemic activity, less toxicity and adverse effect as well as slow metabolism in vivo.
    • 本发明公开了由式(I)表示的三乙酰基-3-羟基苯基腺苷,其制备方法,药物组合物及其用途。 特别地,本发明公开了一种新的2',3',5'-三-O-乙酰基-N6-(3-羟基苯基)腺苷化合物。 使用次黄嘌呤核苷作为起始原料,该化合物通过用乙酸酐乙酰化制备,用亚硫酰氯氯化,并被3-羟基苯胺取代。 本发明还公开了包含三乙酰基-3-羟基苯基腺苷的药物组合物。 所述药物组合物的剂型包括片剂,胶囊,丸剂,注射剂,缓释制剂,控制释放制剂或颗粒递送系统。 用于治疗或预防本发明化合物制备的高脂血症的药物具有明显的降血脂活性,较低毒性和不良反应以及体内代谢缓慢的优点。